Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of E-Flupentixol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 5/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.70 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.70 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.70 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.70 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.70 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.70 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.70 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.70 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.70 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.70 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.70 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.70 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Flupentixol SCHEMBL11427109 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| E-Flupentixol SCHEMBL1153165 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| Z-Flupentixol SCHEMBL29493033 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| Z-Flupentixol SCHEMBL1153162 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| Z-Flupentixol SCHEMBL719323 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| E-Flupentixol SCHEMBL145726 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| Z-Flupentixol SCHEMBL29361845 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| E-Flupentixol SCHEMBL29598791 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| E-Flupentixol SCHEMBL414352 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2ATDP1GMNN | |
| Z-Flupentixol SCHEMBL34200 | 0.99 | CYP3A4 (1.00) | LMNAMEN1KMT2ATDP1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300119-B | Metliquxin and flupentixol eutectic and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-117159708-A | Application of 3 CLpro-targeting compound in inhibiting porcine reproductive and respiratory syndrome virus | 中国农业大学 | 2023-12-05 | — | — | CN | claimed |
| CN-107987053-B | Preparation method of high-purity Z-type flupentixol hydrochloride | 植恩生物技术股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113677671-B | Eutectic crystal of melitracen and flupentixol and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-114105944-A | Preparation method of high-purity Z-type flupentixol and Z-type flupentixol decanoate | 江苏同禾药业有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113677671-A | Eutectic crystal of melitracen and flupentixol and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-113521289-A | Application of 15 effective components of medicine in resisting virus infection | 中国科学院上海药物研究所 | 2021-10-22 | — | — | CN | claimed |
| CN-109674754-B | Flupentixol and melitracen pharmaceutical composition and preparation thereof | 广东赛烽医药科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-109771386-B | Flupentixol melitracen tablet and preparation method thereof | 广东赛烽医药科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-111991397-B | Flupentixol melitracen microsphere and preparation method thereof | 深圳善康医疗健康产业有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-108362792-B | Detection method of flupentixol melitracen compound medicine impurities, new identifiable impurities and safer compound medicine | 成都倍特药业股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-112353805-A | Application of flupentixol in treating and preventing coxsackie virus infection | 北京化工大学 | 2021-02-12 | — | — | CN | claimed |
| WO-2021023119-A1 | CO-CRYSTAL OF MELITRACEN AND FLUPENTIXOL AND PREPARATION METHOD THEREFOR | 江苏恩华药业股份有限公司 | 2021-02-11 | — | — | WO | claimed |
| CN-112300119-A | Eutectic crystal of melitracen and flupentixol and preparation method thereof | 江苏恩华药业股份有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-111991397-A | Flupentixol melitracen microsphere and preparation method thereof | 深圳善康医疗健康产业有限公司 | 2020-11-27 | — | — | CN | claimed |
| WO-2020143394-A1 | FLUPENTIXOL/MELITRACEN PHARMACEUTICAL COMPOSITION AND PREPARATION THEREOF | 广东赛烽医药科技有限公司 | 2020-07-16 | — | — | WO | claimed |
| CN-102002034-B | Method for separating flupentixol hydrochloride isomers | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | claimed |
| CN-102002034-A | Method for separating flupentixol hydrochloride isomers | JIANGSU ENHUA PHARMACEUTICAL CO LTD | 2011-04-06 | — | — | CN | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |